ArticleIranian journal of pathology2026
Interleukin-1β and MicroRNA-146a as Prognostic and Diagnostic Markers of Systemic Lupus Erythematosus Complexity.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MicroRNAs in systemic lupus erythematosus: Molecular networks, pathway dysregulation, and therapeutic targeting strategies.Biotechnology notes (Amsterdam, Netherlands) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by dysregulated autoantibody production and diverse clinical manifestations. Despite advances in research, the diagnosis and management of SLE remain challenging. This study evaluated plasma levels of interleukin-1β (IL-1β) and microRNA-146a (miR-146a) in patients with SLE and explored their potential as diagnostic and prognostic biomarkers. Methods: Blood samples were collected from 100 patients with SLE and 100 healthy controls. Patients with SLE were further classified into newly diagnosed (ND; n=50) and under treatment (UT; n=50) subgroups. Plasma IL-1β levels were quantified using ELISA, and circulating miR-146a expression was assessed by quantitative reverse transcription PCR. Results: Patients with SLE exhibited significantly higher plasma levels of IL-1β and miR-146a compared with healthy controls. ND patients demonstrated the highest concentrations of both biomarkers. Among patients with SLE, those with lupus nephritis (LN) showed markedly elevated IL-1β levels compared with those without LN. Longitudinal analysis during a 24-week follow-up indicated that higher baseline IL-1β levels were associated with an increased risk of LN development, supporting its potential prognostic relevance. Conclusion: IL-1β and miR-146a are elevated in patients with SLE, with IL-1β levels correlating with new-onset disease and LN development. These findings suggest that IL-1β and miR-146a may serve as useful biomarkers for diagnosing, monitoring, and predicting disease progression in SLE, although further validation is warranted.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.